Spybiotech Ltd. has entered into a sponsored research agreement with the University of Oxford for the development of a vaccine against Epstein-Barr virus (EBV).

Researchers from Purdue University and the National Institutes of Health (NIH) have identified a potential target for treating Lyme disease, a prevalent tick-borne illness of increasing concern worldwide. Current treatment for Lyme disease is based on long-term administration of broad-spectrum antibiotics, with significant costs and impact on patients’ quality of life.

TFF Pharmaceuticals Inc. has announced it is advancing into preclinical testing multivalent universal influenza vaccine candidates to protect against seasonal and pandemic viruses, in collaboration with Cleveland Clinic.

In a paper published in the May 17, 2024, online issue of Cell, investigators from the Duke Human Vaccine Institute reported that a sequence of three immunizations in the HVTN-133 trial was sufficient for the development of heterologous or broadly neutralizing antibodies (bnAbs) that protected against several strains of HIV. The findings are “a real beachhead,” Barton Haynes told BioWorld. Haynes is the director of the Duke Human Vaccine Institute and the senior author of the paper.

By isolating a single clone from human isolates, researchers from the National Taiwan University College of Medicine aimed to enhance the immunogenicity of the Zika virus (ZIKV).

The Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately ¥1.64 billion (US$10.8 million) in four projects for the development of new drugs for malaria and neglected tropical diseases.